CCXI ChemoCentryx Inc.

7.29
-0.03  -0%
Previous Close 7.32
Open 7.31
Price To book 8.68
Market Cap 355072638
Shares 48,706,809
Volume 89,315
Short Ratio 8.86
Av. Daily Volume 221,074

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171043434
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015117
  3. 8-K - Current report 171014963
  4. 8-K - Current report 17999947
  5. CT ORDER - Confidential treatment order 17937123

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Partner required to continue with Phase 3 program
Vercirnon CCX282
Crohn's disease
Phase 2 top-line data released Dec 12 2014. Partner required for further development.
CCX140
Diabetic nephropathy
Phase 1b early response data released September 1, 2016. Initial PFS data released January 20, 2017.
CCX872
Non-resectable pancreatic cancer
Phase 2 data presented at ASN Kidney Week - November 17, 2016.
CCX168
Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3 initiated December 2016. Enrollment to be completed mid-2018.
CCX168 (ADVOCATE)
Associated vasculitis (AAV)

SEC Filings

  1. CT ORDER - Confidential treatment order 171043434
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015117
  3. 8-K - Current report 171014963
  4. 8-K - Current report 17999947
  5. CT ORDER - Confidential treatment order 17937123
  6. CT ORDER - Confidential treatment order 17920261
  7. 8-K - Current report 17871471
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830798
  9. 8-K - Current report 17830431
  10. DEF 14A - Other definitive proxy statements 17752837